On this page
What should a nonclinical bioanalytical validation report contain?
Identify the analyte, matrix, method version and intended use, then describe the validation experiments, performance, deviations and supported scope. Connect that report to the study-sample analysis using it. Establish whether ICH M10 applies first; its framework does not cover biomarker bioanalysis or immunogenicity assays.
Before you begin
Separate bioanalytical method and validation reports supporting nonclinical evidence. Product release methods in Module 3 are a different task.
What you will prepare: A method-to-study evidence map and report package with explicit handling of method changes and unresolved analytical limitations.
Establish the analyte, matrix and intended use
Begin with what the assay measures and why: analyte, biological matrix, species, assay technology and studies using the result. Distinguish the method procedure, its validation report and the report of actual study-sample analysis. These may have different identifiers and dates. A laboratory method name by itself is not a complete traceability record.
M10 section 1.3 addresses drug/metabolite concentration measurements using its specified quantitative assay methods and study contexts. Its nonclinical scope includes GLP toxicokinetic studies and PK studies serving as clinical surrogates; it excludes biomarker bioanalysis and methods assessing immunogenicity. Establish the measured quantity, assay purpose and study role with the analytical owner before applying its reporting framework. An antidrug-antibody assay does not become an M10 drug-concentration assay because both use ligand binding. For out-of-scope assays, identify the appropriate source and document the intended-use assessment rather than borrowing M10 acceptance criteria.
Within that scope, M10's documentation section distinguishes records retained at the analytical site from report content recommended for submission. Use that distinction when planning the package. Do not attach every laboratory record indiscriminately, or assume the submitted validation report eliminates the need to retain reconstruction records.
Build the method history before writing the synopsis
Create a working cross-reference of method code/version, analyte/matrix, validation report, effective date and associated study-sample report. Add partial or cross-validation evidence where applicable and explain the reason for each method change. M10 section 8.1 supplies the underlying documentation framework; the exact presentation can follow your controlled reporting process.
Request the validation plan, result tables, acceptance criteria actually applied, deviations and investigations. For study-sample reporting, collect sample receipt and storage records, the run disposition and reanalysis rationale. Have the analytical owner resolve whether the validation conditions cover the samples actually analyzed. A missing bridge between matrices or versions is an open analytical question, not an editorial blank to fill.
Keep validation conclusions separate from run results
Describe the method and validated use, then explain its demonstrated performance and limitations. Organize results so that readers can distinguish the validation experiment from routine analysis of study samples. State the source of acceptance criteria and the outcome; do not invent universal numerical limits from a template.
Explain material investigations and changes, with their effect on the final reported concentrations. A changed peak integration, repeat analysis or sample exclusion should be traceable to its documented decision. Coordinate with the pharmacokinetic author before a corrected concentration table is used to recalculate exposure: a corrected analytical report can affect every downstream exposure comparison.
Catch a plausible matrix mismatch
Fictional example: an assay validated in one species' plasma is cited for concentrations generated in another species, and the package contains no documented assessment of that change. The preparer should ask the analytical owner for the relevant suitability or validation evidence and identify the affected studies.
Do not silently edit the matrix name in the validation synopsis. Until the supporting determination is available, keep the scope limitation visible. If the evidence ultimately supports the new use, connect that record to the correct method version and check the affected Module 2 exposure statements.
Trace analytical changes into the exposure conclusions
Keep a method-to-study map before accepting the validation synopsis. This editorial tool connects records that are often written by different teams.
| Link | Information to reconcile | Consequence of a mismatch |
|---|---|---|
| Method to validation | Version, analyte, species and matrix | The cited validation may not cover the intended use |
| Validation to samples | Applicable conditions and sample history | Performance may not support interpretation of those samples |
| Samples to concentration table | Sample IDs, run disposition and controlled output | A result can be assigned to the wrong population or time |
| Concentrations to exposure | Dataset version and calculation output | Exposure estimates may reflect an obsolete analytical result |
| Exposure to conclusion | Report, table and summary references | A scientific comparison may need reassessment |
When a corrected analytical result arrives, ask for its reason, affected samples and final disposition. Keep the analytical correction separate from the pharmacokinetic recalculation and the scientific interpretation of any change. Each can have a different owner and completion date.
Change exercise: a concentration table is corrected after an analytical investigation, but the report's exposure table still uses the earlier output. Obtain the controlled recalculation and have the scientific owner determine whether conclusions change. Do not silently update a single number in the narrative while leaving dependent tables untouched.
Use the ADME report guide to follow the result into the relevant disposition analysis. For toxicokinetics, also check the toxicity report. The purpose of the map is to find affected claims, not to assume that every method change invalidates every study.
Your preparation checklist
0/4 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Are antidrug-antibody assays within ICH M10?
No. M10 excludes bioanalytical methods used to assess immunogenicity, as well as biomarker bioanalysis. An assay does not enter M10 scope merely because it uses ligand binding. Identify what it measures and its intended use before selecting the applicable validation framework.
Is a validation report the same as a study-sample analysis report?
No. Validation establishes the method’s demonstrated performance for an intended use, whereas study-sample reporting describes the analysis of the actual samples. Keep the method, validation evidence, sample results and any changes connected so the reported concentrations can be reconstructed.
Must every analytical-site record be attached to the submission?
M10 distinguishes analytical-site documentation from recommended submitted report content. Use its documentation framework to plan both retention and reporting. Neither attaching everything nor submitting only a short conclusion replaces the need for appropriate reconstruction records and an informative report.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Technical specification
FDA eCTD v4.0 headings and hierarchy ↗Version 2.2, February 2025; Module 4, printed pages 6–10. Technical placement and allowable document types, not a required-study list. Checked September 22, 2026.
Guidance
FDA ICH M10: bioanalytical method validation and study sample analysis ↗Final guidance, November 2022; scope I.C (1.3) and section VIII (8), especially 8.1 and Table 1. Excludes biomarker and immunogenicity bioanalysis; distinguishes site records from submitted report content. Checked September 22, 2026.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 4.2.2.1. A heading identifies placement, not mandatory applicability.